The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Communications and UpdatesFull Access

Response to Grant et al. Letter

To the Editor: While we did not mention the Center for Medicinal Cannabis Research at the University of California, ably headed by Dr. Grant for the past decade, we did not suggest that the “evidence for marijuana’s efficacy is anecdotal”—just the large majority of it! We did say that “indications with the most evidence include spasticity secondary to neurological diseases such as multiple sclerosis (and) pain management, especially neuropathic pain.” These in fact are the subject of the references cited by Grant et al. to prove their point about marijuana efficacy. These also are the relatively rare conditions that most applicants claim as the reason they need medical marijuana cards, and less than 3% of applicants claim such conditions.

Finally, as we noted in our commentary, in 2011 daily marijuana use among high school seniors reached the highest level in 30 years, according to the Monitoring the Future survey conducted annually by researchers at the Institute for Social Research at the University of Michigan. Researchers found, as we pointed out, that “the rate of marijuana use in youths is inversely related to ‘perceived risk’ and ‘perceived social disapproval.’” Surely Grant et al. are not suggesting that the “medical marijuana” referenda and the dispensaries are unrelated to this increase.

We commend Grant et al. for their attempt to evaluate marijuana scientifically and look forward to the day when there will be FDA submissions.

New York
Rockville, Md.

The authors’ disclosures accompany the original commentary.